Turkish Journal of Endocrinology and Metabolism, published by Galenos Publishing. Original Article Purpose: To evaluate whether fbroblast growth factor-23 (FGF-23) has a common role in the pathogenesis of peripheral arterial disease (PAD) and chronic kidney disease (CKD) in type-2 diabetes mellitus (DM). Material and Method: Twenty-one patients with diabetic nephropathy composed the diabetic nephropathy (DM-NP) group and 20 subjects with DM but without NP constituted the DM group. The control group was comprised of 10 age- and gender-matched non-diabetic individuals with CKD. Results: FGF-23 levels were similar in DM-NP and CKD groups (p=0.5). Both groups had higher FGF-23 levels compared to DM group (p<0.001 and p=0.007). PAD was more common in DM than in CKD (p=0.03). In all cases involving DM (e.g., both the DM-NP and DM-groups), FGF-23 levels did not vary with arterial wall changes recorded via Doppler ultrasonography (p=0.5). Discussion: NP and PAD may be independent complications of DM. In DM, FGF-23 may be a marker of NP but not of PAD. Keywords: Diabetes mellitus, fbroblast growth factor-23, nephropathy, peripheral arterial disease, atherosclerosis, arterial calcifcation Amaç: Fibroblast büyüme faktörü-23’ün (FGF-23) tip 2 diyabetes mellituslu (DM) olgularda periferik arter hastalığı (PAH) ile kronik böbrek yetmezliği (KBY) patogenezinde ortak bir rolü olup olmadığını değerlendirmeyi amaçladık. Gereç ve Yöntem: Diyabetik nefropatisi (NP) olan 21 olgu DM-NP grubunu, DM olan ancak NP bulunmayan 20 olgu DM-grubunu oluşturdu. Diyabetik olmayan, yaş ve cinsiyet uyumlu 10 KBY’li olgu da kontrol grubunu oluşturdu. Bulgular: DM-NP ve KBY gruplarında FGF-23 düzeyleri benzer idi (p=0,5). Her iki grupta da FGF-23 düzeyleri DM grubuna göre daha yüksekti (p<0,001 ve p=0,007). PAH DM’de KBY’ye göre daha sık idi (p=0,03). DM bulunan tüm olgularda (DM ve DM-NP grupları) FGF-23 düzeyleri Doppler ultrasonograf ile belirlenen periferik arter değişiklikleri ile ilişkili değildi (p=0,5). Tartışma: NP ve PAH DM’nin birbirinden bağımsız komplikasyonları olabilir. DM’de FGF-23 nefropati belirteci olabilir. Anahtar kelimeler: Diyabetes mellitus, fbroblast büyüme faktörü-23, nefropati, periferik arter hastalığı, ateroskleroz, arteryal kalsifkasyon Address for Correspondence: Esra Hatipoğlu MD, Edirne Government Hospital, Clinic of Endocrinology, Edirne, Turkey Phone: +90 532 485 86 84 E-mail: esuheda@yahoo.com Received: 28/05/2015 Accepted: 03/08/2015 Esra Hatipoğlu, Nurgül Özgür*, Mutlu Niyazoğlu**, Atilla Süleyman Dikici***, Özlem Balcı Ekmekci****, Serkan Yalın*****, Zeynep Osar Siva*, Hasan İlkova* Edirne Government Hospital, Clinic of Endocrinology, Edirne, Turkey *İstanbul University Faculty of Cerrahpaşa, Department of Internal Medicine, Division of Endocrinology and Metabolism, İstanbul, Turkey **İstanbul Research Hospital, Clinic of Endocrinology and Metabolism, İstanbul, Turkey ***İstanbul University Faculty of Cerrahpaşa, Department of Radiology, İstanbul, Turkey ****İstanbul University Faculty of Cerrahpaşa, Department of Biochemistry, İstanbul, Turkey *****İstanbul University Faculty of Cerrahpaşa, Department of Internal Medicine, Division of Nephrology, İstanbul, Turkey Impact of Fibroblast Growth Factor-23 on Peripheral Arterial Disease in Type 2 Diabetes Mellitus: A Comparative Cross-Sectional Pilot Study Tip 2 Diyabetes Mellitusta Fibroblast Büyüme Faktörü-23’ün Periferik Arter Hastalığı Üzerine Etkisi: Bir Karşılaştırmalı Kesitsel Pilot Çalışma Abstract Öz DOI: 10.4274/tjem.3179 Turk J Endocrinol Metab 2015;19:119-123 119 Introduction Diabetes mellitus (DM) is a chronic disease associated with widespread complications; one of the major complications of which is peripheral arterial disease (PAD). If PAD is not recognized and treated promptly, it results in major amputations and increasing DM-associated morbidity and mortality (1,2). Individuals with DM are prone to develop PAD insidiously at an early stage and once PAD develops, it may progress more rapidly than expected (2,3). Therefore, prevention of PAD in those with DM is of the utmost importance. Recognition of the underlying mechanisms and associated risk factors for development of PAD may facilitate prevention.